Entera Bio Ltd. (NASDAQ:ENTX) rose 15.71% in after-hours trading on Wednesday, climbing to $1.62 following the disclosure of a Securities and Exchange Commission filing by Director Steven D. Rubin.
The stock closed regular session down 1.41% at $1.40, according to Benzinga Pro data.
Director Rubin Acquires Shares
According to the filing, Rubin purchased 5,000 ordinary shares at $1.49 each on Feb. 12, bringing his total direct holdings to 15,000 shares. The total value of the transaction amounted to $7,450.
The SEC filing was signed on Tuesday by attorney-in-fact Dana Yaacov-Garbeli.
Trading Metrics, Technical Analysis
Entera Bio has a market capitalization of $64.20 million, with a 52-week high of $3.22 and a 52-week low of $1.
The Relative Strength Index (RSI) of the clinical-stage biopharmaceutical company stands at 45.54.
Over the past 12 months, ENTX has fallen 37.50%.
The stock is positioned about 18% above its 52-week low, placing it near the lower end of its annual range.
In early February, HC Wainwright & Co. reiterated its Buy rating on ENTX, maintaining a $10 price target.
Benzinga’s Edge Stock Rankings indicate that ENTX has a negative price trend across all time frames.
Photo Courtesy: Digineer Station on Shutterstock.com
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Recent Comments